Vaximm AG Shortens Exclusivity Period with BCM Europe to Enhance Licensing Negotiations Vaximm AG announces an updated term sheet with BCM Europe, reducing the exclusivity period to three months to expedite licensing negotiations for its cancer immunotherapy.

Vaximm AG Shortens Exclusivity Period with BCM Europe to Enhance Licensing Negotiations #United_States #Bellevue #VXM01 #Vaximm_AG #BCM_Europe

Vaximm AG Partners with BCM Europe for VXM01 Licensing: A $20M Deal In a significant development, Vaximm AG has entered a $20M term sheet with BCM Europe to explore a potential licensing agreement for VXM01.

Vaximm AG Partners with BCM Europe for VXM01 Licensing: A $20M Deal #None #VXM01 #Vaximm_AG #BCM_Europe

Dr. Andreas Niethammer Appointed CEO of Vaximm AG, Steering Immuno-Oncology Innovation Forward OSR Holdings has named Dr. Andreas Niethammer as CEO of Vaximm AG, advancing its immuno-oncology mission with innovative oral T-cell vaccines targeting cancer.

Dr. Andreas Niethammer Appointed CEO of Vaximm AG, Steering Immuno-Oncology Innovation Forward #United_States #Bellevue #Immuno-Oncology #OSR_Holdings #Vaximm_AG

OSR Holdings Enhances Leadership with Dr. Andreas Niethammer as CMO for Vaximm AG Dr. Andreas Niethammer has been appointed as CMO of Vaximm AG, an OSR Holdings subsidiary, to lead oncology and immunotherapy advancements in clinical trials.

OSR Holdings Enhances Leadership with Dr. Andreas Niethammer as CMO for Vaximm AG #Switzerland #Basel #OSR_Holdings #Vaximm_AG #Dr._Niethammer

Vaximm AG Unveils Promising Results from Their Phase 2a Trial of Innovative Glioblastoma Therapy Vaximm AG announced successful Phase 2a trial results, revealing the safety and potential efficacy of VXM01 combined with Avelumab for glioblastoma treatment.

Vaximm AG Unveils Promising Results from Their Phase 2a Trial of Innovative Glioblastoma Therapy #Switzerland #Basel #VXM01 #Avelumab #Vaximm_AG